{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:52:04Z","timestamp":1791474724302,"version":"4.3.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82330005"],"award-info":[{"award-number":["No.82330005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82070124"],"award-info":[{"award-number":["No.82070124"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82425003"],"award-info":[{"award-number":["No.82425003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01564-1","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:48:05Z","timestamp":1784047685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subsequent CAR-T and engineered antibody for relapsed\/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Yun","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaolin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-2443","authenticated-orcid":false,"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"1564_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2019","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2019;21:207\u201321. 10.1016\/S1470-2045(19)30788-0.","journal-title":"Lancet Oncol"},{"key":"1564_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024;391:408\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403407.","journal-title":"N Engl J Med"},{"key":"1564_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:393\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2405090.","journal-title":"N Engl J Med"},{"key":"1564_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"key":"1564_CR5","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2022","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple Myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2022;41:1265\u201374. https:\/\/doi.org\/10.1200\/JCO.22.00842.","journal-title":"J Clin Oncol"},{"key":"1564_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.clml.2023.11.001","volume":"24","author":"TG Martin","year":"2024","unstructured":"Martin TG, Moreau P, Usmani SZ, Garfall A, Mateos MV, San-Miguel JF, et al. Teclistamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase II MajesTEC-1 study. Clin Lymphoma Myeloma Leuk. 2024;24:194\u2013202. https:\/\/doi.org\/10.1016\/j.clml.2023.11.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1564_CR7","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"key":"1564_CR8","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:2702\u201312. https:\/\/doi.org\/10.1200\/JCO.24.01008.","journal-title":"J Clin Oncol"},{"key":"1564_CR9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.22.00690","volume":"41","author":"J-Q Mi","year":"2022","unstructured":"Mi J-Q, Zhao W, Jing H, Fu W, Hu J, Chen L, et al. Phase II, open-label study of ciltacabtagene autoleucel, an anti-b-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1). J Clin Oncol. 2022;41:1275\u201384. https:\/\/doi.org\/10.1200\/JCO.22.00690.","journal-title":"J Clin Oncol"},{"key":"1564_CR10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","volume":"10","author":"C Li","year":"2024","unstructured":"Li C, Zhou K, Hu Y, Zou D, Chen L, Chen B, et al. Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial. JAMA Oncol. 2024;10:1681\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2024.4879.","journal-title":"JAMA Oncol"},{"key":"1564_CR11","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1182\/blood-2023-184373","volume":"142","author":"C Fu","year":"2023","unstructured":"Fu C, Chen W, Cai Z, Yan L, Wang H, Shang J, et al. Three-year follow-up on efficacy and safety results from phase 1 lummicar study 1 of zevorcabtagene autoleucel in Chinese patients with relapsed or refractory multiple myeloma. Blood. 2023;142:4845.","journal-title":"Blood"},{"key":"1564_CR12","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43:2766\u201371. https:\/\/doi.org\/10.1200\/JCO-25-00760.","journal-title":"J Clin Oncol"},{"key":"1564_CR13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","volume":"29","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Jain MD, Smith EL. Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma. Transpl Cell Ther. 2023;29:418\u201328. https:\/\/doi.org\/10.1016\/j.jtct.2023.04.007.","journal-title":"Transpl Cell Ther"},{"key":"1564_CR14","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387:1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2209900.","journal-title":"N Engl J Med"},{"key":"1564_CR15","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1200\/jco.22.01824","volume":"41","author":"J Xia","year":"2023","unstructured":"Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y, et al. Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase \u2161 trial. J Clin Oncol. 2023;41:2583\u201393. https:\/\/doi.org\/10.1200\/jco.22.01824.","journal-title":"J Clin Oncol"},{"key":"1564_CR16","doi-asserted-by":"publisher","first-page":"E107","DOI":"10.1016\/s2352-3026(22)00372-6","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, et al. GPRC5D CART cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023;10:E107\u2013E16. https:\/\/doi.org\/10.1016\/s2352-3026(22)00372-6.","journal-title":"Lancet Haematol"},{"key":"1564_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2023-181857","volume":"142","author":"S Bal","year":"2023","unstructured":"Bal S, Htut M, Nadeem O, Anderson LD, Ko\u00e7o\u011flu H, Gregory T, et al. BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study. Blood. 2023;142:219 https:\/\/doi.org\/10.1182\/blood-2023-181857.","journal-title":"Blood"},{"key":"1564_CR18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2024-199542","volume":"144","author":"J Richter","year":"2024","unstructured":"Richter J, Thomas SK, Krishnan AY, Laubach JP, Cohen AD, Trudel S, et al. Cevostamab in patients with heavily pretreated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies. Blood. 2024;144:1021 https:\/\/doi.org\/10.1182\/blood-2024-199542.","journal-title":"Blood"},{"key":"1564_CR19","doi-asserted-by":"publisher","unstructured":"Liang X, Wang Y, Luo B, Lin B, Lu W, Tian S, et al. Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-010064.","DOI":"10.1136\/jitc-2024-010064"},{"key":"1564_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/blood.2023023419","volume":"144","author":"J Kim","year":"2024","unstructured":"Kim J, Cho J, Lee MH, Yoon SE, Kim WS, Kim SJ. CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis. Blood. 2024;144:629\u201338. https:\/\/doi.org\/10.1182\/blood.2023023419.","journal-title":"Blood"},{"key":"1564_CR21","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1182\/bloodadvances.2024012773","volume":"8","author":"Puertas B","year":"2024","unstructured":"Puertas B, Fern\u00e1ndez-S\u00e1nchez, Alejo A, Rey-B\u00faa B E, Mart\u00edn-L\u00f3pez AA, P\u00e9rez-L\u00f3pez E, et al. A research center\u2019s experience of T-cell-redirecting therapies in triple-class refractory multiple myeloma. Blood Adv. 2024;8:3478\u201387. https:\/\/doi.org\/10.1182\/bloodadvances.2024012773.","journal-title":"Blood Adv"},{"key":"1564_CR22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712\u20136.","journal-title":"ANZ J Surg"},{"key":"1564_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A, et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024;38:365\u201371. https:\/\/doi.org\/10.1038\/s41375-024-02154-5.","journal-title":"Leukemia"},{"key":"1564_CR24","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.2023023616","volume":"144","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, et al. Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024;144:2375\u201388. https:\/\/doi.org\/10.1182\/blood.2023023616.","journal-title":"Blood"},{"key":"1564_CR25","doi-asserted-by":"publisher","first-page":"24117","DOI":"10.1182\/blood-2024-204158","volume":"144","author":"J Snyder","year":"2024","unstructured":"Snyder J, Graf K, Davis JA, McKenna M, Tiger YK, Laharwal MM, et al. Evaluation of teclistamab in BCMA-directed therapy exposed versus naive in relapsed\/refractory multiple myeloma. Blood. 2024;144:24117\u20138. https:\/\/doi.org\/10.1182\/blood-2024-204158.","journal-title":"Blood"},{"key":"1564_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01259-z","volume":"15","author":"CR Tan","year":"2025","unstructured":"Tan CR, Asoori S, Huang CY, Brunaldi L, Popat R, Kastritis E, et al. Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. Blood Cancer J. 2025;15:53. https:\/\/doi.org\/10.1038\/s41408-025-01259-z.","journal-title":"Blood Cancer J"},{"key":"1564_CR27","doi-asserted-by":"publisher","first-page":"S384","DOI":"10.1016\/j.jtct.2023.12.537","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima D, Davis J, Ahmed N, Jia X, Sannareddy A, Shaikh H, et al. Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience from the US myeloma innovations research collaborative (USMIRC). Transpl Cell Ther. 2024;30:S384 https:\/\/doi.org\/10.1016\/j.jtct.2023.12.537.","journal-title":"Transpl Cell Ther"},{"key":"1564_CR28","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1182\/blood-2023-183085","volume":"142","author":"A Stepanovic","year":"2023","unstructured":"Stepanovic A, Abonour R, Abu Zaid M, Farag S, Lee KP, Suvannasankha A. Teclistamab in relapsed\/refractory multiple myeloma: real-world outcomes at a single academic center in the Midwest. Blood. 2023;142:7359 https:\/\/doi.org\/10.1182\/blood-2023-183085.","journal-title":"Blood"},{"key":"1564_CR29","doi-asserted-by":"publisher","unstructured":"Grajales-Cruz AF, Castaneda O, Hansen DK, Vazquez-Martinez MA, Blue B, Khadka S, et al. Teclistamab induces favorable responses in patients with relapsed and refractory multiple myeloma after prior BCMA-directed therapy. Blood. 2023;142. https:\/\/doi.org\/10.1182\/blood-2023-184928.","DOI":"10.1182\/blood-2023-184928"},{"key":"1564_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024;14:35. https:\/\/doi.org\/10.1038\/s41408-024-01003-z.","journal-title":"Blood Cancer J"},{"key":"1564_CR31","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study. Lancet Haematol. 2025;12:e269\u2013e81. https:\/\/doi.org\/10.1016\/S2352-3026(24)00385-5.","journal-title":"Lancet Haematol"},{"key":"1564_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2025.100001","volume":"1","author":"AJ Vegel","year":"2025","unstructured":"Vegel AJ, Loeffler BT, Lochner J, Friend R, Habib A, McKenna M, et al. Talquetamab in heavily pretreated patients with multiple myeloma, including BCMA-refractory. Blood Immunol Cell Ther. 2025;1:100001. https:\/\/doi.org\/10.1016\/j.bict.2025.100001.","journal-title":"Blood Immunol Cell Ther"},{"key":"1564_CR33","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.1182\/blood-2024-211739","volume":"144","author":"O Castaneda","year":"2024","unstructured":"Castaneda O, Hansen DK, Vazquez-Martinez MA, Modukuri S, Blue B, Fadul J, et al. Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell redirecting therapies. Blood. 2024;144:5168.","journal-title":"Blood"},{"key":"1564_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70114","volume":"9","author":"JH Frenking","year":"2025","unstructured":"Frenking JH, Riedhammer C, Teipel R, Bassermann F, Besemer B, Bewarder M, et al. A German multicenter real-world analysis of talquetamab in 138 patients with relapsed\/refractory multiple myeloma. HemaSphere. 2025;9:e70114. https:\/\/doi.org\/10.1002\/hem3.70114.","journal-title":"HemaSphere"},{"key":"1564_CR35","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1182\/blood-2024-199519","volume":"144","author":"M Delforge","year":"2024","unstructured":"Delforge M, Richter J, Cohen YC, Corradini P, Sborov DW, Lesokhin AM, et al. Biomarker correlates and clinical activity of cevostamab in patients (pts) with triple-class refractory multiple myeloma (MM) who have received \u22651 prior B-cell maturation antigen (BCMA)-targeted bispecific antibody (BsAb): results from the phase I\/II CAMMA 2 study. Blood. 2024;144:4733\u20134. https:\/\/doi.org\/10.1182\/blood-2024-199519.","journal-title":"Blood"},{"key":"1564_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s44228-022-00023-5","volume":"5","author":"T Plesner","year":"2023","unstructured":"Plesner T, Harrison SJ, Quach H, Lee C, Bryant A, Vangsted A, et al. Phase I study of safety and pharmacokinetics of RO7297089, an anti-BCMA\/CD16a bispecific antibody, in patients with relapsed, refractory multiple myeloma. Clin Hematol Int. 2023;5:43\u201351. https:\/\/doi.org\/10.1007\/s44228-022-00023-5.","journal-title":"Clin Hematol Int"},{"key":"1564_CR37","doi-asserted-by":"publisher","unstructured":"Holstein SA, Atrash S, Mian H, Dimopoulos MA, Schjesvold F, Popat R, et al. A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed\/refractory multiple myeloma. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2024027873.","DOI":"10.1182\/blood.2024027873"},{"key":"1564_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100103","volume":"2","author":"M Hultcrantz","year":"2025","unstructured":"Hultcrantz M, Derkach A, Hassoun H, Korde N, Maclachlan K, Mailankody S, et al. Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: a real-world experience. Blood Neoplasia. 2025;2:100103. https:\/\/doi.org\/10.1016\/j.bneo.2025.100103.","journal-title":"Blood Neoplasia"},{"key":"1564_CR39","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","volume":"41","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Lesokhin AM, Mohty M, Niesvizky R, Maisel C, Arnulf B. et al. Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies. J Clin Oncol. 2023;41:8008.","journal-title":"J Clin Oncol"},{"key":"1564_CR40","doi-asserted-by":"publisher","first-page":"7832","DOI":"10.1182\/blood-2024-204276","volume":"144","author":"AF Grajales-Cruz","year":"2024","unstructured":"Grajales-Cruz AF, Hansen DK, Castaneda O, Graeter A, Vazquez-Martinez MA, Modukuri S, et al. Safety and efficacy of standard of care (SOC) elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM), a single center experience. Blood. 2024;144:7832\u20133. https:\/\/doi.org\/10.1182\/blood-2024-204276.","journal-title":"Blood"},{"key":"1564_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2022-157988","volume":"140","author":"C Carlo-Stella","year":"2022","unstructured":"Carlo-Stella C, Mazza R, Manier S, Facon T, Yoon SS, Koh Y, et al. RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study. Blood. 2022;140:397\u20139. https:\/\/doi.org\/10.1182\/blood-2022-157988.","journal-title":"Blood"},{"key":"1564_CR42","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1182\/blood-2021-146072","volume":"138","author":"YC Cohen","year":"2021","unstructured":"Cohen YC, Cohen AD, Delforge M, Hillengass J, Goldschmidt H, Weisel K, et al. Efficacy and safety of ciltacabtagene autoleucel (Cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: updated results from CARTITUDE-2. Blood. 2021;138:3866 https:\/\/doi.org\/10.1182\/blood-2021-146072.","journal-title":"Blood"},{"key":"1564_CR43","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2024-210451","volume":"144","author":"J Waldschmidt","year":"2024","unstructured":"Waldschmidt J, Fandrei D, Vucinic V, W\u00e4sch R, Nogai A, Alsdorf W, et al. Efficacy of anti-BCMA CAR-T cell therapies in multiple myeloma patients with prior exposure to bispecific antibodies- results from a retrospective multi-center registry analysis. Blood. 2024;144:2007 https:\/\/doi.org\/10.1182\/blood-2024-210451.","journal-title":"Blood"},{"key":"1564_CR44","doi-asserted-by":"publisher","unstructured":"Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, et al. Standard-of-care idecabtagene vicleucel for relapsed\/refractory multiple myeloma: a CIBMTR analysis. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2024026216.","DOI":"10.1182\/blood.2024026216"},{"key":"1564_CR45","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41417-023-00712-0","volume":"31","author":"Q Wang","year":"2024","unstructured":"Wang Q, Wei R, Guo S, Min C, Zhong X, Huang H, et al. An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer Gene Ther. 2024;31:420\u20136. https:\/\/doi.org\/10.1038\/s41417-023-00712-0.","journal-title":"Cancer Gene Ther"},{"key":"1564_CR46","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/S2152-2650(23)01644-0","volume":"23","author":"E Lebel","year":"2023","unstructured":"Lebel E, Kfir-Erenfeld S, Asherie N, Grisariu S, Avni B, Elias S, et al. Safety and efficacy of a locally produced novel anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23:S47\u2013S8.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1564_CR47","doi-asserted-by":"publisher","unstructured":"Dholaria B, Shune L, Kin A, McArthur K, Eskew JD, Martin CE, et al. Clinical activity of P-BCMA-ALLO1, a B-cell maturation antigen (BCMA) targeted allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed refractory multiple myeloma (RRMM) patients (pts) following progression on prior BCMA targeting therapy. Cancer Res. 2024;84. https:\/\/doi.org\/10.1158\/1538-7445.Am2024-ct071.","DOI":"10.1158\/1538-7445.Am2024-ct071"},{"key":"1564_CR48","doi-asserted-by":"publisher","unstructured":"Xia J, Sun Q, Zhou D, Li H, Wang Y, Qi Y, et al. Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2025. https:\/\/doi.org\/10.1016\/S2352-3026(25)00048-1.","DOI":"10.1016\/S2352-3026(25)00048-1"},{"key":"1564_CR49","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1182\/blood-2024-201356","volume":"144","author":"S Bal","year":"2024","unstructured":"Bal S, Anderson LD Jr, Nadeem O, Berdeja JG, Rossi A, Gregory T, et al. Efficacy and safety with extended follow-up in a phase 1 study of BMS-986393, a G Protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cell therapy, in patients (pts) with heavily pretreated relapsed\/refractory (RR) multiple myeloma (MM). Blood. 2024;144:922.","journal-title":"Blood"},{"key":"1564_CR50","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1200\/JCO.2024.42.16_suppl.7511","volume":"42","author":"H Huang","year":"2024","unstructured":"Huang H, Hu Y, Zhang M, Wei G, Zhou L, Fu S. et al. OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed\/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS). J Clin Oncol. 2024;42:7511.","journal-title":"J Clin Oncol"},{"key":"1564_CR51","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2023-179147","volume":"142","author":"S Li","year":"2023","unstructured":"Li S, Yuan Z, Liu L, Li Y, Luo L, Chen Y, et al. Safety and efficacy of GPRC5D CAR T cell therapy in relapsed\/refractory multiple myeloma patients. Blood. 2023;142:3472 https:\/\/doi.org\/10.1182\/blood-2023-179147.","journal-title":"Blood"},{"key":"1564_CR52","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1182\/blood-2024-204790","volume":"144","author":"J Du","year":"2024","unstructured":"Du J, Jin L, Gu S, Lu J, He H, Ruan Q, et al. GPRC5D-targeted CAR T-cell therapy CT071 for the treatment of refractory\/relapsed multiple myeloma. Blood. 2024;144:3451.","journal-title":"Blood"},{"key":"1564_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13:117. https:\/\/doi.org\/10.1038\/s41408-023-00886-8.","journal-title":"Blood Cancer J"},{"key":"1564_CR54","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","volume":"8","author":"E Letouz","year":"2024","unstructured":"Letouz E, Moreau P, Munshi N, Samur M, Minvielle S, Touzeau C. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications. Blood Adv. 2024;8:2952\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2023012354.","journal-title":"Blood Adv"},{"key":"1564_CR55","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140:1104\u201318. https:\/\/doi.org\/10.1182\/blood.2022015956.","journal-title":"Blood"},{"key":"1564_CR56","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41:711\u201325.e6. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.008.","journal-title":"Cancer Cell"},{"key":"1564_CR57","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","volume":"38","author":"L Fischer","year":"2024","unstructured":"Fischer L, Grieb N, Born P, Weiss R, Seiffert S, Boldt A, et al. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma. Leukemia. 2024;38:372\u201382. https:\/\/doi.org\/10.1038\/s41375-023-02129-y.","journal-title":"Leukemia"},{"key":"1564_CR58","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","volume":"11","author":"K Rejeski","year":"2024","unstructured":"Rejeski K, Jain MD, Shah NN, Perales M-A, Subklewe M. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. Lancet Haematol. 2024;11:e459\u2013e70. https:\/\/doi.org\/10.1016\/S2352-3026(24)00077-2.","journal-title":"Lancet Haematol"},{"key":"1564_CR59","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/bjh.18747","volume":"202","author":"W Kitamura","year":"2023","unstructured":"Kitamura W, Asada N, Naoi Y, Abe M, Fujiwara H, Ennishi D, et al. Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy. Br J Haematol. 2023;202:294\u2013307. https:\/\/doi.org\/10.1111\/bjh.18747.","journal-title":"Br J Haematol"},{"key":"1564_CR60","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3324\/haematol.2023.283888","volume":"109","author":"H Hashmi","year":"2024","unstructured":"Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, et al. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2024;109:1514\u201324. https:\/\/doi.org\/10.3324\/haematol.2023.283888.","journal-title":"Haematologica"},{"key":"1564_CR61","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/blood.2024024965","volume":"145","author":"CL Freeman","year":"2025","unstructured":"Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, et al. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025;145:1645\u201357. https:\/\/doi.org\/10.1182\/blood.2024024965.","journal-title":"Blood"},{"key":"1564_CR62","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145:85\u201397. https:\/\/doi.org\/10.1182\/blood.2024025945.","journal-title":"Blood"},{"key":"1564_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12:868. https:\/\/doi.org\/10.1038\/s41467-021-21177-5.","journal-title":"Nat Commun"},{"key":"1564_CR64","doi-asserted-by":"publisher","unstructured":"Da Via MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27. https:\/\/doi.org\/10.1038\/s41591-021-01245-5.","DOI":"10.1038\/s41591-021-01245-5"},{"key":"1564_CR65","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood-2022-168903","volume":"140","author":"MK Samur","year":"2022","unstructured":"Samur MK, Martin N, Thompson E, Fulciniti M, Aktas-Samur A, Kaiser S, et al. Differences in single cells between BCMA-targeting CAR T-cell therapy responders and non-responders reveals initial resistance and acquired resistance are driven by different factors. Blood. 2022;140:2106\u20137. https:\/\/doi.org\/10.1182\/blood-2022-168903.","journal-title":"Blood"},{"key":"1564_CR66","doi-asserted-by":"publisher","unstructured":"Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11. https:\/\/doi.org\/10.1126\/scitranslmed.aau7746.","DOI":"10.1126\/scitranslmed.aau7746"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01564-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01564-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01564-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:02:40Z","timestamp":1791471760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01564-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1564"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01564-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8750940\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"During the preparation of this work, the authors used ChatGPT in order to refine and polish the writing and enhance readability. After using this tool\/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.","order":2,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"174"}}